Verastem, Inc. (0LOV.L)

USD 4.46

(-3.44%)

Total Liabilities Summary of Verastem, Inc.

  • Verastem, Inc.'s latest annual total liabilities in 2023 was 71.18 Million USD , up 49.36% from previous year.
  • Verastem, Inc.'s latest quarterly total liabilities in 2024 Q2 was 65.73 Million USD , down -14.98% from previous quarter.
  • Verastem, Inc. reported annual total liabilities of 47.65 Million USD in 2022, up 125.84% from previous year.
  • Verastem, Inc. reported annual total liabilities of 21.1 Million USD in 2021, down -45.99% from previous year.
  • Verastem, Inc. reported quarterly total liabilities of 77.31 Million USD for 2024 Q1, up 8.62% from previous quarter.
  • Verastem, Inc. reported quarterly total liabilities of 71.81 Million USD for 2023 Q3, up 4.07% from previous quarter.

Annual Total Liabilities Chart of Verastem, Inc. (2023 - 2011)

Historical Annual Total Liabilities of Verastem, Inc. (2023 - 2011)

Year Total Liabilities Total Liabilities Growth
2023 71.18 Million USD 49.36%
2022 47.65 Million USD 125.84%
2021 21.1 Million USD -45.99%
2020 39.07 Million USD -71.66%
2019 137.87 Million USD -9.85%
2018 152.93 Million USD 376.34%
2017 32.1 Million USD 183.33%
2016 11.33 Million USD 6.65%
2015 10.62 Million USD 7.51%
2014 9.88 Million USD 26.46%
2013 7.81 Million USD 218.07%
2012 2.45 Million USD -96.58%
2011 71.8 Million USD 0.0%

Peer Total Liabilities Comparison of Verastem, Inc.

Name Total Liabilities Total Liabilities Difference
Editas Medicine, Inc. 150.05 Million USD 52.561%
Dynavax Technologies Corporation 375.02 Million USD 81.019%
Supernus Pharmaceuticals, Inc. 487.46 Million USD 85.397%
Perrigo Company plc 6.04 Billion USD 98.822%
Illumina, Inc. 4.36 Billion USD 98.37%
Thermo Fisher Scientific Inc. 51.88 Billion USD 99.863%
Iovance Biotherapeutics, Inc. 195.73 Million USD 63.633%
Walgreens Boots Alliance, Inc. 68.85 Billion USD 99.897%
IQVIA Holdings Inc. 20.56 Billion USD 99.654%
Heron Therapeutics, Inc. 256.47 Million USD 72.245%
Regeneron Pharmaceuticals, Inc. 7.1 Billion USD 98.998%
Unity Biotechnology, Inc. 37.29 Million USD -90.885%
Waters Corporation 3.47 Billion USD 97.952%
Biogen Inc. 12.04 Billion USD 99.409%
Sangamo Therapeutics, Inc. 82.43 Million USD 13.645%
Evolus, Inc. 209.68 Million USD 66.052%
Adicet Bio, Inc. 37.12 Million USD -91.77%
Cara Therapeutics, Inc. 68.75 Million USD -3.528%
bluebird bio, Inc. 424.62 Million USD 83.236%
Esperion Therapeutics, Inc. 660.79 Million USD 89.227%
FibroGen, Inc. 585.72 Million USD 87.847%
Agilent Technologies, Inc. 4.91 Billion USD 98.553%
Corbus Pharmaceuticals Holdings, Inc. 35.17 Million USD -102.362%
Homology Medicines, Inc. 118.53 Million USD 39.945%
Geron Corporation 146.12 Million USD 51.286%
Alnylam Pharmaceuticals, Inc. 4.05 Billion USD 98.243%
Amicus Therapeutics, Inc. 617.7 Million USD 88.476%
Myriad Genetics, Inc. 312.9 Million USD 77.25%
Viking Therapeutics, Inc. 20.07 Million USD -254.666%
Intellia Therapeutics, Inc. 250.8 Million USD 71.618%
Zoetis Inc. 9.29 Billion USD 99.234%
Abeona Therapeutics Inc. 49.17 Million USD -44.756%
Mettler-Toledo International Inc. 3.5 Billion USD 97.969%
BioMarin Pharmaceutical Inc. 1.89 Billion USD 96.234%
Vertex Pharmaceuticals Incorporated 5.14 Billion USD 98.618%
Kala Pharmaceuticals, Inc. 48.44 Million USD -46.94%
Ionis Pharmaceuticals, Inc. 2.6 Billion USD 97.266%
Atara Biotherapeutics, Inc. 264.73 Million USD 73.111%
Nektar Therapeutics 267.04 Million USD 73.344%
Axsome Therapeutics, Inc. 397.25 Million USD 82.081%
Aclaris Therapeutics, Inc. 40.22 Million USD -76.963%
Sarepta Therapeutics, Inc. 2.4 Billion USD 97.04%
OPKO Health, Inc. 622.47 Million USD 88.564%
Exelixis, Inc. 678.44 Million USD 89.508%
Neurocrine Biosciences, Inc. 1.01 Billion USD 93.017%
Corcept Therapeutics Incorporated 114.81 Million USD 37.999%
Anavex Life Sciences Corp. 12.53 Million USD -467.935%
uniQure N.V. 624.01 Million USD 88.592%
Imunon, Inc. 8.53 Million USD -734.483%
Blueprint Medicines Corporation 918.64 Million USD 92.251%
Insmed Incorporated 1.66 Billion USD 95.716%
Halozyme Therapeutics, Inc. 1.64 Billion USD 95.684%
Agios Pharmaceuticals, Inc. 126.09 Million USD 43.548%
TG Therapeutics, Inc. 169.08 Million USD 57.9%
Incyte Corporation 1.59 Billion USD 95.529%
Emergent BioSolutions Inc. 1.18 Billion USD 93.996%